NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
Rhea-AI Summary
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, has announced its upcoming financial results release for Q4 and full-year 2024. The results will be disclosed after market close on March 4, 2025. The company will host a conference call at 1:30 PM Pacific Time / 4:30 PM Eastern Time on the same day.
Investors can access the live webcast and participate in the call via telephone by dialing +1-877-407-3982 with Conference ID 13751530. The webcast recording will be available for at least 90 days on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, NPCE gained 5.80%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2024 after market close on Tuesday, March 4, 2025. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1706647&tp_key=43fdbb668b. Individuals interested in participating in the call via telephone may access the call by dialing +1-877-407-3982 and referencing Conference ID 13751530. The webcast will be archived on the company’s investor relations website at https://investors.neuropace.com/news-and-events/events and will be available for replay for at least 90 days after the event.
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When will NeuroPace (NPCE) release its Q4 and full-year 2024 earnings?
How can investors access NPCE's Q4 2024 earnings call?
What time is NeuroPace's (NPCE) Q4 2024 earnings call?
How long will NPCE's Q4 2024 earnings call recording be available?
